# Veneno Technologies Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/veneno-technologies-co

- Industry: Biotechnology
- Headquarters: Tsukuba-shi, Japan
- Website: www.veneno.jp/
- Total disclosed funding: $1.7M
- Latest round: Series A (Jan 24, 2022)
- Investors on record: 3

## About

Based in Ibaraki, Japan, and established in 2020, Veneno Technologies Co., Ltd. creates therapeutic disulfide-rich peptides targeting drug target transmembrane proteins which includes ion channels, transporters, and GPCRs. Veneno Technologies Co., Ltd. has also developed technologies that enable the practical application of DRP molecules, and PERISS (Intra Periplasm Secretion and Selection). DRPs are considered to be the next-generation modality for drug discovery and development. DRPs have a unique knot structure with multiple disulfide bonds in the molecule. Due to the rigidity of such a framework, DRPs are highly stable to pH, heat, and enzymes, especially in comparison with linear peptides. Similar to venoms, DRPs are bioactive peptides with high potency and selectivity. PERISS is a new screening method based on evolutionary molecular engineering. In the PERISS cycle, the DRP genetic variants undergo molecular selection by phenotype, and by repeating this cycle, the target DRP candidate can be efficiently obtained within a short time.

## Funding rounds

- Series A, Jan 24, 2022, $1.7M — SBI Investment, Tsukuba Institute of Research, SBI Regional Activation Support Co., Ltd.

## Investors

- SBI Investment (https://capitalatlas.ai/funds/sbi-investment) — Series A
- Tsukuba Institute of Research (https://capitalatlas.ai/funds/tsukuba-institute-of-research) — Series A
- SBI Regional Activation Support Co., Ltd. — Series A